Medtronic’s Evolut trial outcome could shift US TAVR market
Evolut showed less bioprosthetic valve dysfunction, prosthetic valve thrombosis and haemodynamic structural valve dysfunction ...
Express Healthcare4d
Medtronic’s Evolut trial outcome could alter US TAVR market: GlobalData
The preliminary results look promising for the Evolut for specific patients. The trial consists of mostly women, who have ...
Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy
Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...
Medscape4d
Better 5-Year Valve Performance With TAVI Than Surgery
Patients with symptomatic severe aortic stenosis undergoing CoreValve or Evolut TAVI have better 5-year bioprosthetic valve ...
FDA issues Medtronic embolization device recall and correction notice
In a notice posted to the agency’s website, the FDA noted that on January 30, 2025, Medtronic (MDT) Neurovascular sent all affected customers ...
Yahoo Finance5d
Medtronic plc (MDT)
After hours: March 20 at 6:57:29 p.m. EDT Loading Chart for MDT ...